other material
confidence high
sentiment positive
materiality 0.60
IN8bio presents INB-619 preclinical data at ACR showing deep B cell depletion with minimal cytokine release
IN8BIO, INC.
- INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.
- INB-619 showed minimal IL-6 secretion at concentrations far lower than marketed TCEs, suggesting reduced CRS risk.
- INB-619 selectively expanded γδ T cells without activating αβ T cells, supporting a safer safety profile.
- Data presented at 2025 ACR Convergence; INB-619 is a potential first-in-class pan-γδ T cell engager targeting CD19.